Skip to main content
Two drugs show promise against treatment-resistant breast cancer
12/13/2019

Two studies published in The New England Journal of Medicine describe therapies that show promise against treatment-resistant metastatic breast cancer. T-DXd shrank HER2-positive tumors by at least 30% in 61% of the treatment cohort, and tucatinib along with Herceptin and chemotherapy extended progression-free survival, including in about 25% of patients whose cancer had metastasized to the brain.

Full Story: